검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Sorafenib Tosylate (Sorafenib Tosylate) Alliance for Clinical Trials in On…·Recurrent Melanoma ORR 69%·t½ 1.21 h |
|---|---|
Overview Program | Sorafenib Tosylate |
Overview Company | Alliance for Clinical Trials in Oncology |
Overview Modality | ANTIBODY |
Overview Target | Recurrent Melanoma |
Overview Indication | Liver Cancer |
Overview Phase | PHASE_2 |
Overview Status | ACTIVE |
MoA Biomarker | biomarkers Egfr, Hmox1, Lgmn identified in NAFLD |
PK/PD Half-life | 1.21 h |
PK/PD Species | Dog, ration, optimization, and in , vitro cytotoxicity study |
PK/PD Animal (cat.) | Dog |
PK/PD Experiment | Pharmacokinetic |
Toxicology Species | Dog, ration, optimization, and in , vitro cytotoxicity study |
Toxicology Animal (cat.) | Dog |
Toxicology Major finding | Lipid-Extruded PEGylated Liposomes of Repurposed Sorafenib for Triple-Negative Breast Cancer: A Mechanistically Enhanced Nanoplatform with Improved In Vivo Pharmacokinetics and Targeted Biodistribution.. Sorafenib Tosylate (SRT), a multikinase inhibitor originally approved for several solid tumors, has been repurposed for potential application in triple-negative breast cancer (TNBC) due to its mul… |
Clinical Primary efficacy | ORR 69% |
Clinical ORR | 69% |
Clinical Result source | ClinicalTrials.gov NCT00098254 |
Clinical Data Tier / Score | A · 55 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 12일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Sorafenib Tosylate (Sorafenib Tosylate) Alliance for Clinical Trials in On…·Recurrent Melanoma ORR 69%·t½ 1.21 h |
|---|---|
Overview Program | Sorafenib Tosylate |
Overview Company | Alliance for Clinical Trials in Oncology |
Overview Modality | ANTIBODY |
Overview Target | Recurrent Melanoma |
Overview Indication | Liver Cancer |
Overview Phase | PHASE_2 |
Overview Status | ACTIVE |
MoA Biomarker | biomarkers Egfr, Hmox1, Lgmn identified in NAFLD |
PK/PD Half-life | 1.21 h |
PK/PD Species | Dog, ration, optimization, and in , vitro cytotoxicity study |
PK/PD Animal (cat.) | Dog |
PK/PD Experiment | Pharmacokinetic |
Toxicology Species | Dog, ration, optimization, and in , vitro cytotoxicity study |
Toxicology Animal (cat.) | Dog |
Toxicology Major finding | Lipid-Extruded PEGylated Liposomes of Repurposed Sorafenib for Triple-Negative Breast Cancer: A Mechanistically Enhanced Nanoplatform with Improved In Vivo Pharmacokinetics and Targeted Biodistribution.. Sorafenib Tosylate (SRT), a multikinase inhibitor originally approved for several solid tumors, has been repurposed for potential application in triple-negative breast cancer (TNBC) due to its mul… |
Clinical Primary efficacy | ORR 69% |
Clinical ORR | 69% |
Clinical Result source | ClinicalTrials.gov NCT00098254 |
Clinical Data Tier / Score | A · 55 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 12일 (1일 전) |
추천 비교
추천 비교